SAN DIEGO-- (BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results